Communiqués Unicycive Therapeutics, Inc.

Actions

UNCY

US90466Y2028

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 08/07/2026			Varia. 5j.	Varia. 1 janv.
5,430 ^USD	0,00 %		+2,84 %	-5,89 %

30/06	Les plus fortes baisses à la mi-séance	MT
30/06	Unicycive Therapeutics reçoit une lettre de réponse complète de la FDA concernant la nouvelle demande d'autorisation de mise sur le marché de l'oxylanthanum carbonate	CI

Communiqués

06/07	Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses	NE
02/07	UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton	NE
30/06	Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)	AQ
14/05	Unicycive Therapeutics : May 2026 Corporate Presentation	PU
12/05	Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update	AQ
04/05	Unicycive Therapeutics : May 2026 Corporate Presentation	PU
09/04	Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
30/03	Unicycive Therapeutics : March 2026 Corporate Presentation	PU
30/03	Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update	AQ
06/03	Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm	NE
05/03	Unicycive Therapeutics : March 2026 Corporate Presentation	PU
17/02	Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf	NE
06/02	Unicycive Therapeutics : February 2026 Corporate Presentation	PU
04/02	Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit	AQ
30/01	Unicycive Therapeutics : January 2026 Corporate Presentation	PU
29/01	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission	AQ
07/01	Unicycive Therapeutics : January 2026 Corporate Presentation	PU
29/12	Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)	AQ
01/12	Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf	NE
25/11	Unicycive Therapeutics to Participate in Upcoming Investor Events in December	AQ
12/11	Unicycive Therapeutics : November 2025 Corporate Presentation	PU
12/11	Unicycive Therapeutics : Earnings Release Q3 2025	PU
12/11	Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update	AQ
03/11	Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference	AQ
30/10/25	Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference	AQ